Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 7321 AL 7335

Late onset Alzheimer's disease in older people

Isik AT.

Clin Interv Aging. 2010 Oct 11;5:307-11. doi: 10.2147/CIA.S11718.

Factors of error and effort in memory intervention for patients with Alzheimer's disease and amnesic syndrome

Mimura M, Komatsu S.

Psychogeriatrics. 2010 Dec;10(4):179-86. doi: 10.1111/j.1479-8301.2010.00339.x.

A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease

Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K.

Int J Geriatr Psychiatry. 2011 Sep;26(9):937-43. doi: 10.1002/gps.2630. Epub 2010 Dec 28.

Biological markers of amyloid beta-related mechanisms in Alzheimer's disease

Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K.

Exp Neurol. 2010 Jun;223(2):334-46. doi: 10.1016/j.expneurol.2009.09.024. Epub 2009 Oct 6.

Total and phosphorylated tau protein as biological markers of Alzheimer's disease

Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ.

Exp Gerontol. 2010 Jan;45(1):30-40. doi: 10.1016/j.exger.2009.10.010. Epub 2009 Oct 22.

ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's disease

Stone DJ, Molony C, Suver C, Schadt EE, Potter WZ.

Pharmacogenomics J. 2010 Jun;10(3):161-4. doi: 10.1038/tpj.2009.58. Epub 2009 Dec 8.

The serum protein and lipid oxidation marker levels in Alzheimer's disease and effects of cholinesterase inhibitors and antipsychotic drugs therapy

Sinem F, Dildar K, Gökhan E, Melda B, Orhan Y, Filiz M.

Curr Alzheimer Res. 2010 Aug;7(5):463-9. doi: 10.2174/156720510791383822.

[Pathobiology of Alzheimer's disease and biomarker development]

Arai H, Okamura N, Waragai M, Furukawa K, Yanai K, Kudo Y.

Nihon Yakurigaku Zasshi. 2010 Jan;135(1):3-7. doi: 10.1254/fpj.135.3.

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow K, Hampel H, Weiner M, Zetterberg H.

Nat Rev Neurol. 2010 Mar;6(3):131-44. doi: 10.1038/nrneurol.2010.4. Epub 2010 Feb 16.

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall

Mattsson N, Blennow K, Zetterberg H.

Clin Chem Lab Med. 2010 May;48(5):603-7. doi: 10.1515/CCLM.2010.131.

Impact of the CD40-CD40L dyad in Alzheimer's disease

Giunta B, Rezai-Zadeh K, Tan J.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):149-55. doi: 10.2174/187152710791012099.

Advanced glycation end products as biomarkers and gerontotoxins - A basis to explore methylglyoxal-lowering agents for Alzheimer's disease?

Krautwald M, Münch G.

Exp Gerontol. 2010 Oct;45(10):744-51. doi: 10.1016/j.exger.2010.03.001. Epub 2010 Mar 6.

Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible

Reiman EM, Langbaum JB, Tariot PN.

Biomark Med. 2010 Feb;4(1):3-14. doi: 10.2217/bmm.09.91.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias